Pharmafile Logo

News and Press Releases

European Commission Approves ADCETRIS (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD  

· Approval Based on Updated Positive Overall Survival Results from the phase 3 ECHELON-1 Study for Stage III & IV Hodgkin Lymphoma  · First Significant Improvement in Overall Survival in Two Decades...

Category: Pharmaceutical
Posted: October 23, 2023

Takeda Pharmaceutical Company
61 Aldwych, London, WC2B 4AE, UK

SOPHiA GENETICS Enters New Collaboration with Memorial Sloan Kettering Cancer Center and AstraZeneca to Address Global Inequalities in Comprehensive Cancer Care

The three companies will collaborate to improve global access to advanced cancer testing and data, broadening access to cutting-edge science 18 October 2023 -- Boston, US and Rolle, Switzerland --...

Category: Biotechnology
Posted: October 19, 2023

SOPHiA Genetics
La Pièce 12, CH-1180 Rolle, Switzerland

AstraZeneca reinforces commitment to protecting the most vulnerable from serious infectious diseases at IDWeek 2023

Real-world data from INFORM study demonstrate increased risk of severe COVID-19 outcomes among all individuals with immunocompromising conditions and highlight need for additional protection FluMist Quadrivalent data support the potential...

Category: Clinical Trials
Posted: October 12, 2023

AstraZeneca
Medical.InformationUK@astrazeneca.com
PLC 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA UK

MSD’s WELIREG▼(belzutifan) made available for the treatment of eligible adults with von Hippel-Lindau (VHL) disease in Scotland

Scotland is the first European country to accept belzutifan as a treatment for adult patients with von Hippel-Lindau (VHL) disease who require therapy for VHL-associated renal cell carcinoma (RCC), central...

Category: Pharmaceutical
Posted: October 9, 2023

Merck
IECustomerrelations@merckgroup.com
1 rue Jacques Monod, Site Montesquieu, 33650 Martillac, France

Moderna Announces Positive Phase 1/2 Data from mRNA-1083, the Company’s Combination Vaccine Against Influenza and COVID-19

mRNA-1083 showed strong immunogenicity against influenza and COVID-19, with an acceptable reactogenicity and safety profile, compared to licensed standalone vaccines Company to begin phase 3 trial of mRNA-1083 in adults...

Category: Clinical Trials, Drug Discovery
Posted: October 4, 2023

Moderna
info@modernatx.com
Global Headquarters 200 Technology Square Cambridge, MA 02139

Signant Health Launches Signant Biotech to Accelerate and Streamline Clinical Development for Emerging Biopharmaceutical Organisations

3 October 2023 -- Philadelphia, US -- Signant Health, the leader in evidence generation for modern clinical trials, announced today the launch of Signant Biotech – an integrated clinical research...

Category: Clinical Trials
Posted: October 4, 2023

Signant Health
media@signanthealth.com
4000 Chemical Road Suite 300 Plymouth Meeting, PA 19462

Shionogi Presents New Ensitrelvir Clinical and Real-World Data Reinforcing Potential Across COVID-19 Populations at ESWI 2023

New exploratory analysis of phase 3 SCORPIO-SR study data in Asia suggests that ensitrelvir may reduce the risk of persistent and new late-onset symptoms associated with long COVID-19 over one...

Category: Clinical Trials
Posted: September 20, 2023

SHIONOGI
contact@shionogi.eu
33 Kingsway, London, WC2B 6UF, UK

Mural Health Raises $8m Led by Bessemer Venture Partners to Accelerate Growth

Funding enables Mural Health to expand its Mural Link platform to modernise the clinical trial participant experience 19 September 2023 -- Pennsylvania, US -- Mural Health Technologies, a next-generation clinical...

Category: Clinical Trials
Posted: September 20, 2023

Mural Health Technologies, Inc.
product@muralhealth.com
1189 Lancaster Ave, Berwyn, PA 19312

Invitation to learn from the best: Evening of insights and networking will honour a clinical data management stalwart

Prof Deborah Ashby to give the 2023 Sally Hollis Memorial Lecture in Macclesfield 13 September 2023 -- London, UK and North Carolina, US -- A leading global expert on clinical...

Category: Clinical Trials
Posted: September 18, 2023

PHASTAR
tellmemore@phastar.com
Unit 2, 2A Bollo Ln, Chiswick, London W4 5LE